Morgan Stanley has given GW Pharmaceuticals (GWPH) its vote of confidence, stamping the leader in cannabis-based drugs with a bullish “overweight” rating and a $103.00 price target for the stock on account of the upside potential of epilepsy drug Epidiolex and the company’s “novel platform.” Upon the pre-market release of the bank’s upgrade, the stock jumped from its Monday close of $46.04 to an opening price of $50.10. And the stock continued to roar throughout the trading day Tuesday.
Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV
For more content from TheStreet visit: http://thestreet.com
Check out all our videos: http://youtube.com/user/TheStreetTV
Follow TheStreet on Twitter: http://twitter.com/thestreet
Like TheStreet on Facebook: http://facebook.com/TheStreet
Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet
Follow TheStreet on Google+: http://plus.google.com/+TheStreet
source
